Skip to main content
SpringerLink
Log in

Management of Patients with Multiple SCCs/Field Cancerization

  • Chapter
  • First Online:
High-Risk Cutaneous Squamous Cell Carcinoma

  • 643 Accesses

Abstract

Optimal management of patients with one or multiple cutaneous squamous cell carcinomas (cSCC) should take into account both the characteristics of the tumor itself (tumor risk factors) as well as the clinical setting within which the neoplasia arises (patient risk factors). Use of cyclical topical therapy has been added to surgical excision of individual tumors in the treatment of actinic keratosis and in situ cSCC in patients with large regions of sun-damaged skin (field disease), with good success in reducing overall burden of premalignant and early in situ disease. Early evidence suggests that such topical field therapy of actinically damaged skin decreases invasive cSCC formation as well. Follow up of patients with severe actinic damage and/or a history of multiple cSCCs may be performed within the setting of a dedicated high-risk skin cancer dermatology clinic where available to allow for proactive care and close surveillance. Education, prevention, and early intervention are very important tools in the management of patients with field disease and multiple cSCCs.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Stockfleth E. The paradigm shift in treating actinic keratosis: a comprehensive strategy. J Drugs Dermatol. 2012;11(12):1462–7.

    CAS  PubMed  Google Scholar 

  2. Braakhuis BJ, Tabor MP, Kummer JA, Leemans CR, Brakenhoff RH. A genetic explanation of Slaughter’s concept of field cancerization: evidence and clinical implications. Cancer Res. 2003;63:1727–30.

    CAS  PubMed  Google Scholar 

  3. Boddie AW, Fischer EP, Byers RM. Squamous carcinoma of the lower lip in patients under 40 years of age. South Med J. 1977;70(6):711–2.

    Article  PubMed  Google Scholar 

  4. Czarnecki D, Staples M, Mar A, Giles G, Meehan C. Metastases from squamous cell carcinoma of the skin in southern Australia. Dermatology. 1994;189(1):52–4.

    Article  CAS  PubMed  Google Scholar 

  5. Holman CD, Armstrong BK, Evans PR, Lumsden GJ, Dallimore KJ, Meehan CJ, et al. Relationship of solar keratosis and history of skin cancer to objective measures of actinic skin damage. Br J Dermatol. 1984;110(2):129–38.

    Article  CAS  PubMed  Google Scholar 

  6. Glogau RG. The risk of progression to invasive disease. J Am Acad Dermatol. 2000;42(1 Pt 2):23–4.

    Article  CAS  PubMed  Google Scholar 

  7. Dodson JM, DeSpain J, Hewett JE, Clark DP. Malignant potential of actinic keratoses and the controversy over treatment. A patient-oriented perspective. Arch Dermatol. 1991;127(7):1029–31.

    Article  CAS  PubMed  Google Scholar 

  8. Wallingford SC, Russell SA, Vail A, Proby CM, Lear JT, Green AC. Actinic keratoses, actinic field change and associations with squamous cell carcinoma in renal transplant recipients in Manchester, UK. Acta Derm Venereol. 2015;95:830–4.

    PubMed  Google Scholar 

  9. Schwartz R. The actinic keratosis. A perspective and update. Dermatol Surg. 1997;23(11):1009–19.

    Article  CAS  PubMed  Google Scholar 

  10. Mittelbronn MA, Mullins DL, Ramos-Caro FA, Flowers FP. Frequency of pre-existing actinic keratosis in cutaneous squamous cell carcinoma. Int J Dermatol. 1998;37:677–81.

    Article  CAS  PubMed  Google Scholar 

  11. Czarnecki D, Meehan CJ, Bruce F, Culjak G. The majority of cutaneous squamous cell carcinomas arise in actinic keratoses. J Cutan Med Surg. 2002;6:207–9.

    Article  CAS  PubMed  Google Scholar 

  12. Slaughter DP, Southwick HW, SMejkal W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer. 1953;6(5):963–8.

    Article  CAS  PubMed  Google Scholar 

  13. Ceilley RI, Jorizzo JL. Current issues in the management of actinic keratosis. J Am Acad Dermatol. 2013;68(1):S28–38.

    Article  PubMed  Google Scholar 

  14. Krawtchenko N, Roewert-Huber J, Ulrich M, Mann I, Sterry W, Stockfleth E. A randomized study of topical 5% immiquimod vs topical 5-fluorouracil vs cryosurgery in immunocompetent patients wtih actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up. Br J Dermatol. 2007;157(Suppl):34–40.

    Article  CAS  PubMed  Google Scholar 

  15. Ulrich C. Topical treatment of field cancerization. Cancer Treat Res. 2009;146:439–46.

    Article  CAS  PubMed  Google Scholar 

  16. Mastrolonardo M. Topical diclofenac 3% gel plus cryotherapy for treatment of multiple and recurrent actinic keratoses. Clin Exp Dermatol. 2009;34:33–5.

    Article  CAS  PubMed  Google Scholar 

  17. Dm A. Combination of topical 5-fluorouracil wtih cryotherapy for treatment of actinic keratoses. J Dermatol Surg Oncol. 1983;9:403–4.

    Article  Google Scholar 

  18. Soltani-Arabshahi R, Tristani-Firouzi P. Chemoprevention of nonmelanoma skin cancer. Facial Plast Surg. 2013;29(5):373–83.

    Article  CAS  PubMed  Google Scholar 

  19. Stockfleth E TD, Braathen L, Evidence- and consensus-based (S3) Guidelines for the Treatment of Actinic Keratosis - International League of Dermatological Societies in cooperation with the European. J Eur Acad Dermatol Venereol. 2015;29(11):2069–79. doi: 10.1111/jdv.13180. Epub 2015 Sep 14.

    Google Scholar 

  20. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med. 2003;348(17):1681–91.

    Article  PubMed  Google Scholar 

  21. Barta U, Grafe T, Wollina U. Radiation therapy for extensive actinic keratosis. J Eur Acad Dermatol Venereol. 2000;14(4):293–5.

    Article  CAS  PubMed  Google Scholar 

  22. Greenberg J, Zwald F. Management of skin cancer in solid-organ transplant recipients: a multidisciplinary approach. Dermatol Clin. 2011;29(2):231–41.

    Article  CAS  PubMed  Google Scholar 

  23. Weinberg AS, Ogle C, Shim EK. Metastatic cutaneous squamous cell carcinoma: an update. Dermatol Surg. 2007;33:885–99.

    CAS  PubMed  Google Scholar 

  24. Zwald FO, Brown M. Skin cancer in solid organ transplant recipients: advances in therapy and management: part I. Epidemiology of skin cancer in solid organ transplant recipients. J Am Acad Dermatol. 2011;65(2):253–61. quiz 62.

    Article  PubMed  Google Scholar 

  25. Otley CC. Organization of a specialty clinic to optimize the care of organ transplant recipients at risk for skin cancer. Dermatol Surg. 2000;26(7):709–12.

    Article  CAS  PubMed  Google Scholar 

  26. Terushkin V, Braga JC, Dusza SW, Scope A, Busam K, Marghoob AA, Gill M, Halpern AC. Agreement on the clinical diagnosis and management of cutaneous squamous neoplasms. Dermatol Surg. 2010;10:1514–20.

    Article  Google Scholar 

  27. TE Quaedvlieg PJ, Thissen MR, Krekels GA. Actinic keratosis: how to differentiate the good from the bad ones? Eur J Dermatol. 2006;16(4):335–9.

    CAS  PubMed  Google Scholar 

  28. Berman B, Cohen DE, Amini S. What is the role of field-directed therapy in the treatment of actinic keratosis? Part 1: overview and investigational topical agents. Cutis. 2012;89(5):241–50.

    PubMed  Google Scholar 

  29. Lin JS, Eder M, Weinmann S, Zuber SP, Beil TL, Plaut D, et al. U.S. Preventive Services Task Force evidence syntheses, formerly systematic evidence reviews. Behavioral counseling to prevent skin cancer: systematic evidence review to update the 2003 US Preventive Services Task Force recommendation. Rockville: Agency for Healthcare Research and Quality (US); 2011.

    Google Scholar 

  30. National Cancer Institute Cancer Trends Progress Report - 2011/2012 Update http://progressreport.cancer.gov 22 August 2014.

  31. Ulrich C, Jurgensen JS, Degen A, Hackethal M, Ulrich M, Patel MJ, et al. Prevention of non-melanoma skin cancer in organ transplant patients by regular use of a sunscreen: a 24 months, prospective, case-control study. Br J Dermatol. 2009;161 Suppl 3:78–84.

    Article  PubMed  Google Scholar 

  32. Hofbauer GF, Anliker M, Arnold A, Binet I, Hunger R, Kempf W, et al. Swiss clinical practice guidelines for skin cancer in organ transplant recipients. Swiss Med Wkly. 2009;139(29–30):407–15.

    CAS  PubMed  Google Scholar 

  33. Berg D, Otley CC. Skin cancer in organ transplant recipients: epidemiology, pathogenesis, and management. J Am Acad Dermatol. 2002;47(1):1–17. quiz 8-20.

    Article  PubMed  Google Scholar 

  34. Shimizu I, Cruz A, Chang KH, Dufresne RG. Treatment of squamous cell carcinoma in situ: a review. Dermatol Surg. 2011;37(10):1394–411.

    Article  CAS  PubMed  Google Scholar 

  35. Morton C, Campbell S, Gupta G, Keohane S, Lear J, Zaki I, et al. Intraindividual, right-left comparison of topical methyl aminolaevulinate-photodynamic therapy and cryotherapy in subjects with actinic keratoses: a multicentre, randomized controlled study. Br J Dermatol. 2006;155(5):1029–36.

    Article  CAS  PubMed  Google Scholar 

  36. Freeman M, Vinciullo C, Francis D, Spelman L, Nguyen R, Fergin P, et al. A comparison of photodynamic therapy using topical methyl aminolevulinate (Metvix) with single cycle cryotherapy in patients with actinic keratosis: a prospective, randomized study. J Dermatolog Treat. 2003;14(2):99–9106.

    Article  CAS  PubMed  Google Scholar 

  37. Szeimies RM, Karrer S, Radakovic-Fijan S, Tanew A, Calzavara-Pinton PG, Zane C, et al. Photodynamic therapy using topical methyl 5-aminolevulinate compared with cryotherapy for actinic keratosis: a prospective, randomized study. J Am Acad Dermatol. 2002;47(2):258–62.

    Article  CAS  PubMed  Google Scholar 

  38. Kaufmann R, Spelman L, Weightman W, Reifenberger J, Szeimies RM, Verhaeghe E, et al. Multicentre intraindividual randomized trial of topical methyl aminolaevulinate-photodynamic therapy vs. cryotherapy for multiple actinic keratoses on the extremities. Br J Dermatol. 2008;158(5):994–9.

    Article  CAS  PubMed  Google Scholar 

  39. Chen K, Craig JC, Shumack S. Oral retinoids for the prevention of skin cancers in solid organ transplant recipients: a systematic review of randomized controlled trials. Br J Dermatol. 2005;152(3):518–23.

    Article  CAS  PubMed  Google Scholar 

  40. Smit JV, Cox S, Blokx WA, van de Kerhof PC, de Jongh GJ, de Jong EM. Actinic keratoses in renal transplant recipients do not improve with calcipotriol cream and all-trans retinoic acid cream as monotherapies or in combination during a 6-week treatment period. Br J Dermatol. 2002;147(4):816–8.

    Article  CAS  PubMed  Google Scholar 

  41. Weinstock MA, Bingham SF, Digiovanna JJ, Rizzo AE, Marcolivio K, Hall R, et al. Tretinoin and the prevention of keratinocyte carcinoma (basal and squamous cell carcinoma of the skin): a veterans affairs randomized chemoprevention trial. J Invest Dermatol. 2012;132(6):1583–90.

    Article  CAS  PubMed  Google Scholar 

  42. Eaglsterin WH, Weinstien GD, Frost P. Fluorouracil: mechanims of action in human skin and actinic keratoses. I. Effect on DNA synthesis in vivo. Arch Dermatol. 1970;101:132–9.

    Article  Google Scholar 

  43. Tsai E, Zackheim H, Kim Y. Topical and intralesional chemotherapeutic agents. In: Wolverton S, editor. Comprehensive dermatologic drug therapy. 2nd ed. Philadelphi: Elsevier; 2007. p. 643–53.

    Google Scholar 

  44. Askew DA, Mickan SM, Soyer HP, Wilkinson D. Effectiveness of 5-fluorouracil treatment for actinic keratosis--a systematic review of randomized controlled trials. Int J Dermatol. 2009;48(5):453–63.

    Article  CAS  PubMed  Google Scholar 

  45. Perrett CM, McGregor JM, Warwick J, Karran P, Leigh IM, Proby CM, et al. Treatment of post-transplant premalignant skin disease: a randomized intrapatient comparative study of 5-fluorouracil cream and topical photodynamic therapy. Br J Dermatol. 2007;156(2):320–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Pearlman DL. Weekly pulse dosing: effective and comfortable topical 5-fluorouracil treatment of multiple facial actinic keratoses. J Am Acad Dermatol. 1991;25(4):665–7.

    Article  CAS  PubMed  Google Scholar 

  47. Sauder DN. Immunomodulatory and pharmacologic properties of imiquimod. J Am Acad Dermatol. 2000;43(1 Pt 2):S6–11.

    Article  CAS  PubMed  Google Scholar 

  48. Ito T, Amakawa R, Kaisho T, Hemmi H, Tajima K, Uehira K, et al. Interferon-alpha and interleukin-12 are induced differentially by Toll-like receptor 7 ligands in human blood dendritic cell subsets. J Exp Med. 2002;195(11):1507–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Kovach BT, Stasko T. Use of topical immunomodulators in organ transplant recipients. Dermatol Ther. 2005;18(1):19–27.

    Article  PubMed  Google Scholar 

  50. Patel GK, Goodwin R, Chawla M, Laidler P, Price PE, Finlay AY, et al. Imiquimod 5% cream monotherapy for cutaneous squamous cell carcinoma in situ (Bowen’s disease): a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2006;54(6):1025–32.

    Article  PubMed  Google Scholar 

  51. Ulrich C, Busch JO, Meyer T, Nindl I, Schmook T, Sterry W, et al. Successful treatment of multiple actinic keratoses in organ transplant patients with topical 5% imiquimod: a report of six cases. Br J Dermatol. 2006;155(2):451–4.

    Article  CAS  PubMed  Google Scholar 

  52. Smith KJ, Germain M, Skelton H. Squamous cell carcinoma in situ (Bowen’s disease) in renal transplant patients treated with 5% imiquimod and 5% 5-fluorouracil therapy. Dermatol Surg. 2001;27(6):561–4.

    CAS  PubMed  Google Scholar 

  53. Cantisani C, Lazic T, Richetta AG, Clerico R, Mattozzi C, Calvieri S. Imiquimod 5% cream use in dermatology, side effects and recent patents. Recent Pat Inflamm Allergy Drug Discov. 2012;6(1):65–9.

    Article  CAS  PubMed  Google Scholar 

  54. Hanger C, Dalrymple J, Hepburn D. Systemic side effects from topical imiquimod. N Z Med J. 2005;118(1223):U1682.

    PubMed  Google Scholar 

  55. Pirard D, Vereecken P, Melot C, Heenen M. Three percent diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses: a meta-analysis of the recent studies. Arch Dermatol Res. 2005;297(5):185–9.

    Article  CAS  PubMed  Google Scholar 

  56. Solaraze. Diclofenac sodium 3% – package insert. Fairfield: Doak Dermatologics; 2004.

    Google Scholar 

  57. Ulrich C, Johannsen A, Rowert-Huber J, Ulrich M, Sterry W, Stockfleth E. Results of a randomized, placebo-controlled safety and efficacy study of topical diclofenac 3% gel in organ transplant patients with multiple actinic keratoses. Eur J Dermatol. 2010;20(4):482–8.

    PubMed  Google Scholar 

  58. Rosen RH, Gupta AK, Tyring SK. Dual mechanism of action of ingenol mebutate gel for topical treatment of actinic keratoses: rapid lesion necrosis followed by lesion-specific immune response. J Am Acad Dermatol. 2012;66(3):486–93.

    Article  CAS  PubMed  Google Scholar 

  59. Lebwohl M, Swanson N, Anderson LL, Melgaard A, Xu Z, Berman B. Ingenol mebutate gel for actinic keratosis. N Engl J Med. 2012;366(11):1010–9.

    Article  CAS  PubMed  Google Scholar 

  60. Lebwohl M, Shumack S, Stein Gold L, Melgaard A, Larsson T, Tyring SK. Long-term follow-up study of ingenol mebutate gel for the treatment of actinic keratoses. JAMA Dermatol. 2013;149(6):666–70.

    Article  CAS  PubMed  Google Scholar 

  61. Mann M, Berk DR, Petersen J. Chemowraps as an adjuvant to surgery for patients with diffuse squamous cell carcinoma of the extremities. J Drugs Dermatol. 2008;7(7):685–8.

    PubMed  Google Scholar 

  62. Ritchie SA, Patel MJ, Miller SJ. Therapeutic options to decrease actinic keratosis and squamous cell carcinoma incidence and progression in solid organ transplant recipients: a practical approach. Dermatol Surg. 2012;38(10):1604–21.

    Article  CAS  PubMed  Google Scholar 

  63. Tallon B, Turnbull N. 5% Fluorouracil chemowraps in the management of widespread lower leg solar keratoses and squamous cell carcinoma. Australas J Dermatol. 2013;54(4):313–6.

    Article  PubMed  Google Scholar 

  64. Babilas P, Landthaler M, Szeimies R. Photodynamic therapy in dermatology. Eur J Dermatol. 2006;16(4):340–8.

    CAS  PubMed  Google Scholar 

  65. Peng Q, Soler AM, Warloe T, Nesland JM, Giercksky KE. Selective distribution of porphyrins in skin thick basal cell carcinoma after topical application of methyl 5-aminolevulinate. J Photochem Photobiol B. 2001;62(3):140–5.

    Article  CAS  PubMed  Google Scholar 

  66. Morton C, Szeimies RM, Sidoroff A, Braathen L. European guidelines for topical photodynamic therapy part 1: treatment delivery and current indications – actinic keratoses, Bowen’s disease, basal cell carcinoma. J Eur Acad Dermatol Venereol. 2013;27:536–44.

    Article  CAS  PubMed  Google Scholar 

  67. Szeimies RM, Matheson RT, Davis SA, Bhatia AC, Frambach Y, Klövekorn W, Fesq H, Berking C, Reifenberger J, Thaçi D. Topical methyl aminolevulinate photodynamic therapy using red light-emitting diode light for multiple actinic keratoses: a randomized study. Dermatol Surg. 2009;35(4):586–92.

    Article  CAS  PubMed  Google Scholar 

  68. Pariser DM, Lowe NJ, Stewart DM, et al. Photodynamic therapy with topical methyl aminolevulinate for actinic keratosis: results from a prospective randomized multicenter trial. J Am Acad Dermatol. 2003;48:227–32.

    Article  PubMed  Google Scholar 

  69. Tschen EH, Wong DS, Pariser DM, Phase IV ALA-PDT Actinic Keratosis Study Group. Photodynamic therapy using aminolaevulinic acid for patients with nonhyperkeratotic actinic keratoses of the face and scalp: phase IV multicentre clinical trial with 12-month follow up. Br J Dermatol. 2006;155:1262–9.

    Article  CAS  PubMed  Google Scholar 

  70. Dragieva G, Prinz BM, Hafner J, Dummer R, Burg G, Binswanger U, et al. A randomized controlled clinical trial of topical photodynamic therapy with methyl aminolaevulinate in the treatment of actinic keratoses in transplant recipients. Br J Dermatol. 2004;151(1):196–200.

    Article  CAS  PubMed  Google Scholar 

  71. Piaserico S, Belloni Fortina A, Rigotti P, Rossi B, Baldan N, Alaibac M, et al. Topical photodynamic therapy of actinic keratosis in renal transplant recipients. Transplant Proc. 2007;39(6):1847–50.

    Article  CAS  PubMed  Google Scholar 

  72. Willey A, Mehta S, Lee PK. Reduction in the incidence of squamous cell carcinoma in solid organ transplant recipients treated with cyclic photodynamic therapy. Dermatol Surg. 2010;36(5):652–8.

    Article  CAS  PubMed  Google Scholar 

  73. Wiegell SR, Wulf HC, Szeimies RM, Basset-Seguin N, Bissonnette R, Gerritsen MJ, Gilaberte Y, Calzavara-Pinton P, Morton CA, Sidoroff A, Braathen LR. Daylight photodynamic therapy for actinic keratosis: an international consensus: International Society for Photodynamic Therapy in Dermatology. J Eur Acad Dermatol Venereol. 2012;26(6):673–9.

    Article  CAS  PubMed  Google Scholar 

  74. Wiegell SR, Haedersdal M, Philipsen PA, Eriksen P, Enk CD, Wulf HC. Continuous activation of PplX by daylight is as effective as and less painful than conventional photodynamic therapy for actinic keratoses – a randomized, controlled, single-blinded study. Br J Dermatol. 2008;158:740–6.

    Article  CAS  PubMed  Google Scholar 

  75. Wiegell SR, Haedersdal M, Eriksen P, Wulf HC. Photodynamic therapy of actinic keratoses with 8% and 16% methyl aminolevulinate and home-based daylight exposure: a double-blinded randomized clinical trial. Br J Dermatol. 2009;160:1308–14.

    Article  CAS  PubMed  Google Scholar 

  76. Wiegell SR, Fabricius S, Stender IM, et al. A randomized, multicentre study of directed daylight exposure times of 1½ vs. 2½ h in daylightmediated photodynamic therapy with methyl aminolevulinate in patients with multiple thin actinic keratoses of the face and scalp. Br J Dermatol. 2011;164:1083–90.

    Article  CAS  PubMed  Google Scholar 

  77. Humphreys TR, Werth V, Dzubow L, Kligman A. Treatment of photodamaged skin with trichloroacetic acid and topical tretinoin. J Am Acad Dermatol. 1996;34(4):638–44.

    Article  CAS  PubMed  Google Scholar 

  78. Schule R, Rangarajan P, Yang N, Kliewer S, Ransone LJ, Bolado J, et al. Retinoic acid is a negative regulator of AP-1-responsive genes. Proc Natl Acad Sci U S A. 1991;88(14):6092–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Hansen LA, Sigman CC, Andreola F, Ross SA, Kelloff GJ, De Luca LM. Retinoids in chemoprevention and differentiation therapy. Carcinogenesis. 2000;21(7):1271–9.

    Article  CAS  PubMed  Google Scholar 

  80. Wright TI, Spencer JM, Flowers FP. Chemoprevention of nonmelanoma skin cancer. J Am Acad Dermatol. 2006;54(6):933–46. quiz 47-50.

    Article  PubMed  Google Scholar 

  81. Otley CC, Berg D, Ulrich C, Stasko T, Murphy GM, Salasche SJ, et al. Reduction of immunosuppression for transplant-associated skin cancer: expert consensus survey. Br J Dermatol. 2006;154(3):395–400.

    Article  CAS  PubMed  Google Scholar 

  82. Anforth R, Fernandez-Penas P, Long GV. Cutaneous toxicities of RAF inhibitors. Lancet Oncol. 2013;14(1):e11–8.

    Article  CAS  PubMed  Google Scholar 

  83. Su F, Viros A, Milagre C, Trunzer K, Bollag G, Spleiss O, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med. 2012;366(3):207–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Anforth R, Blumetti TC, Clements A, Kefford R, Long GV, Fernandez-Penas P. Systemic retinoids for the chemoprevention of cutaneous squamous cell carcinoma and verrucal keratosis in a cohort of patients on BRAF inhibitors. Br J Dermatol. 2013;169(6):1310–3.

    Article  CAS  PubMed  Google Scholar 

  85. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366(8):707–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  86. Patton TJ, Zirwas MJ, Wolverton SE. Systemic retinoids. In: Wolverton SE, editor. Comprehensive dermatologic drug therapy. 2nd ed. Philadelphia: Elsevier; 2007. p. 275–300.

    Google Scholar 

  87. Kovach BT, Sams HH, Stasko T. Systemic strategies for chemoprevention of skin cancers in transplant recipients. Clin Transplant. 2005;19(6):726–34.

    Article  PubMed  Google Scholar 

  88. Zwald FO, Brown M. Skin cancer in solid organ transplant recipients: advances in therapy and management: part II. Management of skin cancer in solid organ transplant recipients. J Am Acad Dermatol. 2011;65(2):263–79. quiz 80.

    Article  PubMed  Google Scholar 

  89. Peramiquel L, Dalmau J, Puig L, Roe E, Fernandez-Figueras MT, Alomar A. Inflammation of actinic keratoses and acral erythrodysesthesia during capecitabine treatment. J Am Acad Dermatol. 2006;55(5 Suppl):S119–20.

    Article  PubMed  Google Scholar 

  90. Endrizzi BT, Lee PK. Management of carcinoma of the skin in solid organ transplant recipients with oral capecitabine. Dermatol Surg. 2009;35(10):1567–72.

    Article  CAS  PubMed  Google Scholar 

  91. Jirakulaporn T, Endrizzi B, Lindgren B, Mathew J, Lee PK, Dudek AZ. Capecitabine for skin cancer prevention in solid organ transplant recipients. Clin Transplant. 2011;25(4):541–8.

    Article  CAS  PubMed  Google Scholar 

  92. Endrizzi B, Ahmed RL, Ray T, Dudek A, Lee P. Capecitabine to reduce nonmelanoma skin carcinoma burden in solid organ transplant recipients. Dermatol Surg. 2013;39(4):634–45.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, Dermatologists of Southwest Ohio, INC, Cincinnati, OH, USA

    Sasha Jenkins Haberle MD, MPH

  2. Department of Dermatology, Emory University, Atlanta, GA, USA

    Lauren Rimoin MD

  3. Aristotle University of Thessaloniki, Papageorgiou Hospital, Thessaloniki, Greece

    Myrto Georgia Trakatelli MD, PhD

  4. St. Pierre Hospital, Bruxelles, Belgium

    Myrto Georgia Trakatelli MD, PhD

  5. Piedmont Transplant Institute, Piedmont Hospital, Atlanta, GA, USA

    Fiona Zwald MD, MRCPI

Authors
  1. Sasha Jenkins Haberle MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lauren Rimoin MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Myrto Georgia Trakatelli MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Fiona Zwald MD, MRCPI
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fiona Zwald MD, MRCPI .

Editor information

Editors and Affiliations

  1. Brigham & Women's Hosp., Dept of Derm., Mohs & Dermatologic Surgery Center, Jamaica Plain, Massachusetts, USA

    Chrysalyne D. Schmults

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Haberle, S.J., Rimoin, L., Trakatelli, M.G., Zwald, F. (2016). Management of Patients with Multiple SCCs/Field Cancerization. In: Schmults, C. (eds) High-Risk Cutaneous Squamous Cell Carcinoma. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-47081-7_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-47081-7_5

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-47080-0

  • Online ISBN: 978-3-662-47081-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation